| LEADER®Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results | Liraglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 428 | Dec 2015 | 41 | results |
| DUAL™ IDual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 302 | May 2012 | 9 | results |
| NCT00856986The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 233 | Apr 2010 | 3 | results |
| LIRA-PRIMEEfficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7.5-9% | Ph 4 | Completed | 232 | Aug 2019 | 2 | results |
| NCT01272219Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Liraglutide Obesity / overweight, Prediabetes / glucose intolerance | — | Ph 3 | Completed | 226 | Mar 2013 | 17 | results |
| LEAD-2To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together | Liraglutide Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 190 | May 2007 | 18 | results |
| Ellipse™Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 185 | Nov 2017 | 2 | results |
| ADJUNCT ONE™The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes | Liraglutide Type 1 diabetes | HbA1c 7-10% | Ph 3 | Completed | 182 | Jun 2015 | 3 | results |
| NCT01128894A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. | Albiglutide, Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 173 | Sep 2011 | 1 | results |
| NCT00700817The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 166 | Jun 2009 | 14 | results |
| NCT01272232Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 161 | Jan 2013 | 13 | results |
| NCT02461589Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes | Liraglutide, Semaglutide Type 2 diabetes | BMI 25-40 | Ph 2 | Completed | 150 | Oct 2016 | 1 | results |
| DUAL™ VIIIA 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | BMI ≥20 | Ph 3 | Completed | 143 | Oct 2018 | 2 | results |
| EAGLEEfficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure | Liraglutide Type 2 diabetes | BMI 25-40 | Ph 4 | Completed | 136 | Oct 2012 | — | results |
| NCT01664247The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification | Liraglutide Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Completed | 132 | Dec 2013 | 1 | results |
| LEAD-1Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 127 | May 2007 | 15 | |
| LEAD-6Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes | Exenatide, Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 125 | Apr 2008 | 16 | results |
| BEGIN™Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin | Liraglutide Type 2 diabetes | — | Ph 3 | Completed | 124 | Jul 2012 | 1 | results |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 124 | May 2018 | 5 | results |
| ADJUNCT TWO™The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes | Liraglutide Type 1 diabetes | HbA1c 7-10% | Ph 3 | Completed | 120 | Apr 2015 | 4 | results |
| NCT03235050A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes | Cotadutide, Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 2 | Completed | 119 | May 2018 | 1 | results |
| LEAD-3To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Terminated | 117 | Nov 2008 | 19 | results |
| NCT02420262A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 117 | Oct 2016 | 3 | results |
| LEAD-5Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 116 | Apr 2007 | 14 | |
| DUAL™ IIIThe Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 109 | Mar 2014 | 3 | results |
| NCT01029886Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes | Exenatide, Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 108 | Jan 2011 | 2 | results |
| NCT02443155A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function | Liraglutide Type 1 diabetes | — | Ph 2 | Completed | 108 | Aug 2018 | 1 | results |
| PIONEER 4Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 108 | Aug 2017 | 7 | results |
| LIRA-SWITCH™Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin | Liraglutide Type 2 diabetes | BMI ≥20 | Ph 4 | Completed | 106 | Jun 2015 | 1 | results |
| NCT01620489Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Liraglutide Renal impairment, Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 97 | Aug 2013 | 4 | results |
| NCT01658501Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 2 | Completed | 93 | Jul 2013 | — | |
| SUSTAIN 10Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 92 | Jul 2018 | 2 | results |
| DUAL™ VA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 91 | Nov 2014 | 10 | results |
| LEAD-4Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 89 | Aug 2007 | 15 | |
| DUALTM IXA Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | BMI ≥20 | Ph 3 | Completed | 88 | Sep 2017 | 1 | results |
| DUAL™IVThe Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy | Liraglutide Type 2 diabetes | HbA1c 7-9% | Ph 3 | Completed | 87 | Oct 2013 | 3 | results |
| DUAL™ IIA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Completed | 86 | Oct 2012 | 7 | results |
| NCT01617434The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI 20-45 | Ph 3 | Completed | 86 | Oct 2013 | 2 | results |
| DUAL™ VIA Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 84 | Dec 2015 | 2 | results |
| NCT02964247LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. | Liraglutide Type 2 diabetes | HbA1c 7-9.5% | Ph 3 | Completed | 82 | May 2018 | 2 | results |
| NCT00696657A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 77 | Feb 2009 | 1 | results |
| DUAL™ I JapanA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. | Liraglutide Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 76 | Dec 2017 | 2 | results |
| NCT01733758A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) | Albiglutide, Liraglutide Type 2 diabetes | BMI 17-40 | Ph 3 | Completed | 74 | Jun 2014 | — | results |
| NCT02453711Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Liraglutide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 74 | Mar 2017 | 2 | results |
| LIRA-LIXI™Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes | Liraglutide, Lixisenatide Type 2 diabetes | BMI ≥20 | Ph 4 | Completed | 61 | Nov 2014 | 2 | results |
| DUAL™A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification | Liraglutide Type 2 diabetes | — | Ph 3 | Completed | 60 | Apr 2015 | — | results |
| NCT02973321A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus | Liraglutide, SAR425899 Obesity / overweight, Type 2 diabetes | — | Ph 2 | Completed | 59 | Dec 2017 | 2 | results |
| AWARD-6A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes | Dulaglutide, Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 57 | Nov 2013 | 3 | results |
| SCALE™ InsulinEffect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 54 | Sep 2018 | 1 | results |
| NCT03856047Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | CagriSema / cagrilintide, Liraglutide Obesity / overweight | — | Ph 2 | Completed | 54 | Mar 2020 | 1 | results |
| NCT03486392A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants | Efinopegdutide, Liraglutide Obesity / overweight | — | Ph 2 | Completed | 51 | Mar 2019 | — | results |
| NCT00614120Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 50 | Feb 2009 | 5 | results |
| NCT02505334A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. | Liraglutide Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Completed | 47 | May 2017 | — | results |
| NCT04373967Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI 18.5-45 | Ph 3 | Unknown | 46 | Dec 2021 | — | |
| NCT02060383Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly | Liraglutide Diabetes (other / unspecified) | — | Ph 4 | Completed | 43 | Feb 2018 | 2 | results |
| NCT01557166Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea | Liraglutide Obesity / overweight, Sleep apnea | BMI ≥30 | Ph 3 | Completed | 42 | Jun 2013 | 6 | results |
| GOALGOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan. | Liraglutide Type 2 diabetes | — | — | Completed | 42 | Oct 2022 | — | |
| NCT01511172Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI 25-40 | Ph 2 | Completed | 41 | Dec 2002 | 2 | |
| LIRA-Ramadan™Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≥20 | Ph 4 | Completed | 41 | Sep 2014 | 2 | results |
| NCT00154401Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c ≤10% | Ph 2 | Completed | 39 | Oct 2005 | 5 | |
| NCT01511198Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent | Liraglutide Obesity / overweight, Type 2 diabetes | BMI 27-42 | Ph 2 | Completed | 39 | Oct 2001 | 2 | |
| DUAL™ II JapanA Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs | Liraglutide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 38 | Nov 2017 | 3 | results |
| NCT00781937Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance | Liraglutide Obesity / overweight | BMI 27-30 | Ph 3 | Completed | 37 | Sep 2010 | 7 | results |
| DUAL™ II ChinaA Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) | Liraglutide Type 2 diabetes | — | Ph 3 | Completed | 37 | Mar 2019 | — | results |
| PRECIDENTDPREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Cardiovascular disease, Type 2 diabetes | Established ASCVD/CKD | Ph 4 | Recruiting | 36 | Mar 2029 | 1 | |
| NCT01512108Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone | Liraglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 36 | Apr 2013 | 2 | results |
| GRADEA Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c 6.8-8.5% | Ph 3 | Completed | 36 | Apr 2021 | 61 | results |
| NCT02638805Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide | Exenatide, Liraglutide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 36 | Oct 2017 | — | |
| DUAL™ I ChinaA Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 36 | Jun 2019 | 1 | results |
| IMPERIUMA Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) | Exenatide, Liraglutide Type 2 diabetes | HbA1c 7.3-10.9% | Ph 4 | Terminated | 34 | Oct 2015 | 1 | results |
| NCT02918279Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | Liraglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 33 | Feb 2019 | 2 | results |
| NCT04775082SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity | Liraglutide Obesity / overweight | Age 6-12 | Ph 3 | Active, not recruiting | 32 | Aug 2023 | 1 | |
| NCT02527200Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | Liraglutide Hypothalamic / syndromic obesity, Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 32 | Nov 2020 | 1 | results |
| NCT04952779Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | — | — | Completed | 32 | Dec 2024 | — | |
| NCT01509755Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7.5-10% | Ph 2 | Completed | 29 | Oct 2001 | 2 | |
| NCT03560336A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea. | Liraglutide Obesity / overweight | — | — | Completed | 28 | Dec 2020 | — | |
| NCT04666987A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy | Liraglutide Type 2 diabetes | HbA1c ≥3% | — | Completed | 28 | Dec 2022 | — | |
| FIGHTFunctional Impact of GLP-1 for Heart Failure Treatment (FIGHT) | Liraglutide Heart failure | EF ≤40% | Ph 2 | Completed | 25 | Oct 2015 | 4 | results |
| NCT02008682The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Completed | 25 | Nov 2014 | 1 | results |
| NCT01572740Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 23 | Nov 2012 | 2 | results |
| FLAMESFibrosis Lessens After Metabolic Surgery | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Bariatric Surgery Candidate, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 35-70 | Ph 4 | Recruiting | 22 | May 2029 | — | |
| INFLAM MOTIONA Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis | Liraglutide Osteoarthritis | BMI 18.5-35 | Ph 2 | Recruiting | 22 | Jul 2026 | — | |
| NCT00943501Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes | Liraglutide Obesity / overweight, Type 2 diabetes | HbA1c 6.5-11% | Ph 1 | Completed | 20 | Sep 2011 | 2 | |
| NCT02205528A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Liraglutide, RG7697 / MAR709 Obesity / overweight, Type 2 diabetes | — | Ph 2 | Completed | 20 | Sep 2015 | 1 | |
| NCT00422058The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes | Liraglutide Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 19 | Sep 2007 | 6 | results |
| NCT02967757In-market Utilisation of Liraglutide Used for Weight Management in Europe | Liraglutide Obesity / overweight | — | — | Completed | 19 | May 2019 | 1 | |
| STEP 8Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity | Liraglutide, Semaglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 19 | Mar 2021 | 3 | results |
| NCT06113341A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c ≤12% | — | Withdrawn | 19 | Feb 2025 | — | |
| NCT01206101Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation | Liraglutide Type 1 diabetes | — | Ph 2 | Terminated | 16 | Jun 2013 | — | results |
| PIONEER 9Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | Liraglutide, Semaglutide Type 2 diabetes | HbA1c 6.5-9.5% | Ph 3 | Completed | 16 | Jan 2018 | 4 | results |
| VIEW-IranA Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine | Liraglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 16 | Oct 2020 | — | |
| NCT06283641Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. | Liraglutide Obesity / overweight | — | — | Completed | 15 | Jan 2025 | — | |
| NCT01558271A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide, Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 14 | Oct 2013 | 2 | results |
| NCT02113332Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥27.5 | Ph 2 | Completed | 14 | Aug 2014 | 10 | |
| NCT02773355Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients | Liraglutide Obesity / overweight | BMI ≥30 | — | Completed | 14 | Nov 2021 | — | |
| SEVERALSEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | — | Completed | 11 | Nov 2023 | 14 | |
| SCALE™ IBTEffect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting | Liraglutide Obesity / overweight | — | Ph 3 | Completed | 10 | May 2018 | 1 | results |
| NCT02696148A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years | Liraglutide Obesity / overweight | Age 7-11 | Ph 1 | Completed | 9 | Apr 2017 | 1 | |
| PREFERVildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications | Liraglutide Type 2 diabetes | BMI 19-35 | Ph 4 | Completed | 8 | Oct 2012 | 1 | |
| NCT01596504Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin | Liraglutide, Lixisenatide Type 2 diabetes | BMI 20-40 | Ph 2 | Completed | 8 | Jul 2013 | 1 | results |
| REMITiDegLiraRemission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira | Liraglutide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 8 | Jun 2022 | — | |
| NCT01175473Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes | Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 2 | Completed | 7 | Nov 2010 | 1 | results |
| NCT01821846Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | — | — | Completed | 7 | Mar 2017 | — | |
| NCT02889510Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus | Liraglutide Obesity / overweight, Type 2 diabetes | BMI 30-40 | Ph 3 | Completed | 6 | Nov 2019 | 11 | results |
| GLP-1REWINGLP-1 REceptor Agonists and Real World EvIdeNce | Dulaglutide, Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | — | — | Unknown | 6 | Feb 2019 | 6 | |
| ON TARGET DMComparison of Type 2 Diabetes Pharmacotherapy Regimens | Exenatide, Liraglutide Type 2 diabetes | — | — | Completed | 6 | Dec 2024 | 4 | results |
| SPIRITGlycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia | Liraglutide Type 2 diabetes | — | — | Completed | 6 | Jul 2022 | 1 | |
| LIGHT-MCILIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes | Liraglutide Alzheimer's / cognition, Type 2 diabetes | BMI ≥19 | Not applicable | Active, not recruiting | 5 | Dec 2025 | 4 | |
| NCT01919489Liraglutide Hospital Discharge Trial | Liraglutide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 4 | Completed | 5 | Aug 2020 | — | results |
| NCT02754817A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | — | — | Completed | 5 | Oct 2016 | 1 | |
| STRIVESaxenda in Obesity Services (STRIVE Study) | Liraglutide Obesity / overweight | BMI ≥35 | Ph 4 | Completed | 5 | Feb 2021 | 2 | results |
| BESTMEDBESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-11% | — | Unknown | 5 | Jun 2024 | 3 | |
| NCT02321878Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®) | Liraglutide Type 2 diabetes | — | — | Completed | 5 | Jun 2017 | — | |
| NCT01472640The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus | Liraglutide Heart failure, Type 2 diabetes | EF ≤45% | Not applicable | Completed | 4 | Sep 2015 | 2 | |
| RISE AdultRISE Adult Medication Study | Liraglutide Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 4 | Feb 2019 | 15 | results |
| NCT01870297A Study of LY3025876 in Participants With Diabetes | Liraglutide Type 2 diabetes | BMI ≥23 | Ph 1 | Completed | 4 | Dec 2014 | — | results |
| NCT01890993Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe | Liraglutide Type 2 diabetes | — | — | Completed | 4 | Jun 2014 | — | |
| NCT02055014Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥35 | Ph 4 | Unknown | 4 | Mar 2017 | — | |
| NCT02488057Improving Beta Cell Function in Mexican American Women With Prediabetes | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, Prediabetes / glucose intolerance | BMI 30-42 | Ph 4 | Completed | 4 | Mar 2019 | 10 | |
| NCT02898506Incretin-based Therapy in Late Preclinical Type 1 Diabetes | Liraglutide Prediabetes / glucose intolerance, Type 1 diabetes | HbA1c 2-12% | Ph 2 | Completed | 4 | Jun 2021 | 1 | |
| NCT02908087Incretin-based Therapy in Early Diagnosed Type 1 Diabetes | Liraglutide Type 1 diabetes | — | Ph 2 | Completed | 4 | May 2021 | 1 | |
| NCT03757130Multiple Ascending Dose Study of AMG 598 in Adults With Obesity | Liraglutide Obesity / overweight | BMI ≥30 | Ph 1 | Completed | 4 | Dec 2019 | — | results |
| LIRADIALEfficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients | Liraglutide Chronic kidney disease, Obesity / overweight, Renal impairment, Type 2 diabetes | BMI ≥30 | Ph 2 | Unknown | 4 | Jan 2023 | 12 | |
| NCT06400615Study That Tests AD109 in Patients Taking GLP-1 Drugs | Liraglutide, Semaglutide, Tirzepatide Obesity / overweight, Sleep apnea | BMI 27-43 | Ph 2 | Completed | 4 | Dec 2024 | — | |
| DIRECTGLPDIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c ≥7.5% | Not applicable | Completed | 4 | Jul 2015 | — | |
| LITOPLiraglutide Treatment in Obese Infertile PCOS Women | Liraglutide Obesity / overweight, PCOS, Reproductive / infertility | BMI ≤35 | Ph 4 | Recruiting | 3 | May 2029 | — | |
| NCT01394341Liraglutide Treatment to Patients With Severe Renal Insufficiency | Liraglutide Chronic kidney disease, Type 2 diabetes | HbA1c ≥6.5% | Ph 4 | Completed | 3 | Oct 2013 | 3 | |
| NCT01725126To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes | Liraglutide Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI 18-35 | Ph 2 | Completed | 3 | Sep 2013 | 1 | results |
| PILGRIMPerioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus | Liraglutide Perioperative / gastric aspiration risk, Type 2 diabetes | — | Not applicable | Completed | 3 | Jan 2017 | 1 | |
| LIPTLIPT - Liraglutide in Polycystic Ovary Syndrome | Liraglutide PCOS | BMI ≥25 | Ph 4 | Completed | 3 | Dec 2015 | 1 | results |
| NCT02611232Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults | Liraglutide Type 1 diabetes | — | Ph 2 | Unknown | 3 | Jun 2024 | 1 | |
| NCT03555994A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. | Cotadutide, Liraglutide Obesity / overweight, Type 2 diabetes | BMI 27-40 | Ph 2 | Completed | 3 | Apr 2021 | 1 | results |
| INTENSIFYA Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c ≤12% | — | Completed | 3 | Dec 2020 | — | |
| NCT04311411A Study of Tirzepatide in Overweight and Very Overweight Participants | Liraglutide, Tirzepatide Obesity / overweight | BMI 27-50 | Ph 1 | Completed | 3 | Dec 2022 | 1 | results |
| LASARESafety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee | Liraglutide Osteoarthritis | — | Ph 1 | Completed | 3 | Oct 2023 | 1 | results |
| NCT05756764Anti-obesity Pharmacotherapy and Inflammation | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 2 | Jan 2026 | — | |
| NCT05925959Preoperative Weight Loss for Open Abdominal Wall Reconstruction | Liraglutide, Semaglutide Obesity / overweight | BMI 40-55 | Not applicable | Recruiting | 2 | Jun 2027 | 1 | |
| NCT06836284The Evira Study: Additional Support During Obesity Treatment | Liraglutide, Semaglutide Obesity / overweight | Age 12-17 | Not applicable | Recruiting | 2 | Apr 2027 | — | |
| NCT01425580Liraglutide and Heart Failure in Type 2 Diabetes | Liraglutide Heart failure, Type 2 diabetes | EF ≤50% | Ph 2 | Completed | 2 | Aug 2016 | 3 | |
| NCT01511692Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes | Liraglutide Obesity / overweight, Type 2 diabetes | BMI 27-40 | Ph 1 | Completed | 2 | Sep 2007 | 1 | |
| FPSEffects of Obesity Treatments on Food Preferences and Metabolism | Exenatide, Liraglutide Bariatric Surgery Candidate, Obesity / overweight | BMI ≥30 | — | Completed | 2 | Oct 2017 | — | results |
| NCT01753362Liraglutide In Overweight Patients With Type 1 Diabetes | Liraglutide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 3 | Completed | 2 | Dec 2017 | — | results |
| NCT02231658Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion | Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 1 | Terminated | 2 | Jul 2018 | 1 | |
| NCT02351232The Lira Pump Trial | Liraglutide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 2/3 | Completed | 2 | Oct 2016 | 1 | |
| NCT02870231Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity | Liraglutide Obesity / overweight | BMI 25-39.9 | Ph 1 | Completed | 2 | Sep 2017 | — | |
| NCT03466021Effects of Liraglutide in Chronic Obstructive Pulmonary Disease | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, Pulmonary Disease, Chronic Obstructive | BMI ≥27 | Ph 4 | Completed | 2 | May 2020 | 1 | |
| NCT03632759Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D | Liraglutide Type 1 diabetes | HbA1c ≤8.5% | Early Ph 1 | Completed | 2 | Nov 2021 | 1 | |
| NCT03737240IDegLira HIGH Trial | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 2 | Jul 2022 | — | results |
| NCT03795701To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity | Liraglutide Obesity / overweight | BMI 30-50 | Not applicable | Completed | 2 | May 2022 | — | |
| NCT04027023Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus | Exenatide, Liraglutide Type 2 diabetes | HbA1c ≤10% | Ph 4 | Unknown | 2 | Apr 2021 | — | |
| NCT05268627Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight | BMI ≥30 | Not applicable | Unknown | 2 | Jan 2023 | — | |
| NCT06533527Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Dulaglutide, Liraglutide, Semaglutide, Tirzepatide Perioperative / gastric aspiration risk | — | Ph 4 | Completed | 2 | May 2025 | 4 | results |
| T4RTrial for People With Established Type 2 Diabetes During Ramadan | Liraglutide Type 2 diabetes | HbA1c 7-11% | Ph 4 | Completed | 2 | Dec 2012 | — | |
| NCT03115099A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes | Liraglutide Healthy volunteers, Type 2 diabetes | BMI ≥18.5 | Ph 1 | Completed | 2 | Apr 2018 | — | |
| NCT01511393An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) | Dulaglutide, Exenatide, Liraglutide, Semaglutide Oncology | — | — | By invitation | 1 | Dec 2039 | 1 | |
| NCT02944500Saxenda: Underlying Mechanisms and Clinical Outcomes | Liraglutide Obesity / overweight | BMI ≥30 | Ph 4 | Active, not recruiting | 1 | Jun 2027 | 2 | |
| LiraGooDLiraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥24 | Ph 4 | Recruiting | 1 | Jan 2025 | — | |
| NCT03878706The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination | GLP-1 / incretin class catch-all, Liraglutide Cardiovascular disease, Heart failure, Type 2 diabetes | — | — | Recruiting | 1 | Dec 2026 | 26 | |
| CER-4-T2DComparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | — | — | Active, not recruiting | 1 | May 2026 | — | |
| GOAL-AFOutcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF ) | Liraglutide Atrial fibrillation, Obesity / overweight | — | — | Active, not recruiting | 1 | Jun 2025 | 1 | |
| NCT06361238Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery | Liraglutide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Recruiting | 1 | Mar 2027 | — | |
| NCT06449235Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Not yet recruiting | 1 | Apr 2025 | — | |
| NCT06581120GLP_1 RA Ultrasound Study | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight, Perioperative / gastric aspiration risk, Type 2 diabetes | BMI ≥35 | — | By invitation | 1 | Jul 2026 | — | |
| BalanceImpact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity | Liraglutide Bariatric Surgery, Obesity / overweight | BMI ≥30 | — | Recruiting | 1 | May 2027 | — | |
| NCT06903923Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight | — | Ph 2 | Recruiting | 1 | Feb 2030 | — | |
| METSAFEMetabolic Surgery for Atrial Fibrillation Elimination | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Atrial fibrillation, Bariatric Surgery Candidate, Obesity / overweight | BMI 35-65 | Ph 4 | Not yet recruiting | 1 | Dec 2029 | — | |
| NCT07029009Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) | Liraglutide Diabetes (other / unspecified) | — | Ph 2 | Recruiting | 1 | Aug 2026 | — | |
| BETTER-GLP1Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Feeding And Eating Disorders, Obesity / overweight | BMI ≥40 | — | Recruiting | 1 | Nov 2027 | — | |
| TiLi-BONETirzepatide vs Liraglutide in Bone | Liraglutide, Tirzepatide Obesity / overweight | BMI ≥40 | — | Recruiting | 1 | Dec 2026 | 36 | |
| DASH-CKMHUsing Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide Metabolic syndrome | — | — | Active, not recruiting | 1 | Jun 2029 | — | |
| NCT07225816Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | Liraglutide, Semaglutide Obesity / overweight, Perioperative / gastric aspiration risk | — | Ph 1 | Recruiting | 1 | Jun 2026 | — | |
| MESSAGEEfficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control | Liraglutide Type 2 diabetes | BMI ≥20 | Ph 4 | Recruiting | 1 | Dec 2027 | — | |
| ADIPO-CKDClinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | — | — | Recruiting | 1 | Jul 2027 | 15 | |
| BetaBeta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Type 2 diabetes | BMI 23-45 | Ph 4 | Active, not recruiting | 1 | Dec 2027 | 11 | |
| NCT07590219Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity | Liraglutide Obesity / overweight | Age 6-12 | Ph 4 | Active, not recruiting | 1 | Apr 2027 | 12 | |
| NCT00154414Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤30 | Ph 2 | Completed | 1 | May 2006 | 2 | |
| NCT00393718Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤35 | Ph 3 | Completed | 1 | Nov 2007 | 4 | results |
| NCT00395746Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI ≤35 | Ph 3 | Completed | 1 | Oct 2007 | 6 | results |
| NCT00620282The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 1 | May 2010 | 3 | results |
| NCT00761540To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo | Liraglutide Healthy volunteers | BMI 19-27 | Ph 1 | Completed | 1 | Dec 2008 | 1 | |
| NCT00873223Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 1 | Completed | 1 | Sep 2009 | 1 | |
| NCT00978393A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers | Liraglutide Healthy volunteers, Obesity / overweight | BMI 30-40 | Ph 1 | Completed | 1 | Jun 2011 | 1 | |
| NCT00983021Safety and Tolerability of NN9068 in Healthy Male Volunteers | Liraglutide Healthy volunteers | BMI 18-27 | Ph 1 | Completed | 1 | Dec 2009 | 1 | |
| NCT00993304A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics | Liraglutide Type 2 diabetes | BMI 18.5-40 | Ph 1 | Completed | 1 | Dec 2010 | 3 | |
| NCT00993720Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes | Liraglutide Type 1 diabetes | BMI 18-27 | Ph 2/3 | Completed | 1 | Oct 2010 | 1 | |
| NCT01208012Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | HbA1c 5.5-7% | Ph 4 | Completed | 1 | Nov 2010 | 1 | |
| Lead-InA Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Apr 2012 | 1 | |
| EVIDENCEObservational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Nov 2013 | 2 | |
| NCT01232946Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Not applicable | Completed | 1 | Sep 2017 | 1 | results |
| NCT01234649Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) | Liraglutide Gestational diabetes, Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥25 | Ph 3 | Completed | 1 | Apr 2019 | 1 | results |
| LEANLiraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis | Liraglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥25 | Ph 2 | Completed | 1 | Jul 2014 | 3 | |
| LIBRALIraglutide and Beta-cell RepAir (LIBRA) Study | Liraglutide Type 2 diabetes | HbA1c 5.5-9% | Ph 3 | Completed | 1 | Dec 2013 | 9 | |
| ROOTSObservational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Mar 2013 | 1 | |
| Lead-PhNon-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Jul 2013 | 1 | |
| LIBRAEffects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes | Liraglutide Bariatric Surgery Candidate, Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI ≤25 | Not applicable | Completed | 1 | Jan 2015 | 2 | |
| ELEGANTLiraglutide and Insulin Therapy in Patients With Type 2 Diabetes | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Not applicable | Unknown | 1 | May 2014 | 1 | |
| LIRAINSStudy of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes | Liraglutide MASH / NAFLD / liver fibrosis, Type 2 diabetes | HbA1c ≥6.5% | Ph 2 | Completed | 1 | Jun 2014 | 1 | |
| NCT01455441The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Jun 2013 | — | |
| NCT01469351Identifying Potential Effects of Liraglutide on Degenerative Changes | Liraglutide Alzheimer's / cognition | — | Not applicable | Completed | 1 | Apr 2013 | 7 | |
| NCT01473953Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects | Liraglutide Healthy volunteers | BMI 20-35 | Ph 1 | Completed | 1 | Mar 2012 | — | results |
| NCT01484262Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2 | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Oct 2014 | 1 | |
| LiratimeTime Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes | Liraglutide Hypertension, Type 2 diabetes | eGFR ≥60 | Ph 4 | Completed | 1 | Jul 2013 | 1 | |
| NCT01505673Adding Liraglutide to High Dose Insulin: Breaking the Cycle | Liraglutide Obesity / overweight, Type 2 diabetes | HbA1c 7.5-11% | Ph 4 | Completed | 1 | Jun 2016 | 2 | results |
| NCT01507272Safety and Tolerability of Liraglutide in Healthy Male Volunteers | Liraglutide Healthy volunteers | BMI 20-27 | Ph 1 | Completed | 1 | Dec 1999 | 2 | |
| NCT01507285Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes | Liraglutide Healthy volunteers, Type 2 diabetes | BMI 19-30 | Ph 1 | Completed | 1 | Nov 1999 | 1 | |
| NCT01507311Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI 24-35 | Ph 1 | Completed | 1 | Dec 1999 | 1 | |
| NCT01507337Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers | Liraglutide Healthy volunteers | BMI 18-30 | Ph 1 | Completed | 1 | Jun 2004 | 1 | |
| NCT01507389Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function | Liraglutide Healthy volunteers, Hepatic impairment | BMI 18.5-40 | Ph 1 | Completed | 1 | Jun 2006 | — | |
| NCT01508806Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function | Liraglutide Healthy volunteers, Renal impairment | — | Ph 1 | Completed | 1 | Mar 2006 | 1 | |
| NCT01508858Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women | Liraglutide Healthy volunteers | BMI 18-30 | Ph 1 | Completed | 1 | Apr 2007 | 1 | |
| NCT01508923Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | — | Ph 2 | Completed | 1 | Feb 2002 | 1 | |
| NCT01508949Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Completed | 1 | Mar 2002 | 1 | |
| NCT01509742Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | — | Ph 1 | Completed | 1 | Nov 2001 | 2 | |
| NCT01511185Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group | Liraglutide Healthy volunteers, Type 2 diabetes | BMI 24-35 | Ph 1 | Completed | 1 | Oct 2001 | 1 | |
| NCT01513525Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers | Liraglutide Healthy volunteers | BMI 18.5-27.5 | Ph 1 | Completed | 1 | May 2007 | 1 | |
| NCT01515592Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers | Liraglutide Healthy volunteers | BMI 18-27 | Ph 1 | Completed | 1 | Apr 2006 | 1 | |
| NCT01516255Effect of Liraglutide on Heart Frequency in Healthy Volunteers | Liraglutide Healthy volunteers | BMI 20-29 | Ph 1 | Completed | 1 | Nov 2006 | 1 | |
| NCT01517555Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI 18.5-40 | Ph 1 | Completed | 1 | May 2007 | 4 | |
| NCT01517568Metabolism and Excretion of Liraglutide in Healthy Male Volunteers | Liraglutide Healthy volunteers | BMI 20-27 | Ph 1 | Completed | 1 | Dec 2006 | 1 | |
| NCT01518166Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH | Liraglutide Healthy volunteers | BMI 18-30 | Ph 1 | Completed | 1 | Apr 2007 | 1 | |
| NCT01536665The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes | Liraglutide Type 1 diabetes | BMI 20-28 | Ph 1 | Completed | 1 | Aug 2012 | 2 | |
| NCT01542242Liraglutide Use in Prader-Willi Syndrome | Liraglutide Hypothalamic / syndromic obesity, Type 2 diabetes | Male | Ph 4 | Terminated | 1 | Mar 2013 | 2 | |
| NCT01562678Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI | Liraglutide Obesity / overweight, Type 2 diabetes | BMI 18-25 | Ph 4 | Completed | 1 | May 2014 | 2 | results |
| ADELANTEA Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7-9% | Ph 4 | Withdrawn | 1 | Dec 2013 | — | |
| AddHope2The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes | Liraglutide Cardiovascular disease, Type 2 diabetes | — | Ph 4 | Completed | 1 | Oct 2014 | 6 | |
| NCT01597531Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding | Liraglutide Bariatric Surgery, Type 2 diabetes | BMI 26-65 | Ph 4 | Terminated | 1 | Jun 2014 | 1 | |
| NCT01599338Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Not applicable | Completed | 1 | Jan 2011 | — | |
| NCT01610934The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY) | Liraglutide Diabetes (other / unspecified) | BMI ≥19 | Ph 2/3 | Completed | 1 | Aug 2013 | 1 | |
| NCT01612468Liraglutide in Type 1 Diabetes | Liraglutide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Feb 2015 | 2 | |
| NCT01615978Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes | Liraglutide Type 2 diabetes | BMI 18.5-30 | Ph 1 | Completed | 1 | Mar 2004 | 1 | |
| NCT01620463Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers | Liraglutide Healthy volunteers | BMI 18-27 | Ph 1 | Completed | 1 | Mar 2003 | 1 | |
| NCT01620476Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers | Liraglutide Healthy volunteers | BMI 18-27 | Ph 1 | Completed | 1 | Mar 2004 | 1 | |
| SAILStudy of Liraglutide in Individuals With Type 2 Diabetes Using Insulin | Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Terminated | 1 | Nov 2015 | — | |
| NCT01664676Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients | Liraglutide Type 2 diabetes | BMI 20-32 | Ph 4 | Completed | 1 | Feb 2014 | — | |
| NCT01677104The Microvascular Function of GLP-1 and Its Analogues | Exenatide, Liraglutide Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI ≤25 | Not applicable | Completed | 1 | Jul 2014 | 1 | |
| NCT01687582Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients | Exenatide, Liraglutide Psoriasis / psoriatic arthritis, Type 2 diabetes | — | Not applicable | Completed | 1 | Dec 2012 | 2 | |
| NCT01695109The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers | Liraglutide Healthy volunteers | BMI 19-25 | Ph 4 | Completed | 1 | Feb 2012 | — | |
| NCT01715428Liraglutide and Cardio-Metabolic Risk Markers | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Dec 2015 | 6 | |
| 1966Liraglutide in Type 1 Diabetes | Liraglutide Type 1 diabetes | BMI 20-40 | Ph 3 | Completed | 1 | Jan 2019 | — | results |
| NCT01722266Liraglutide in the Treatment of Type 1 Diabetes Mellitus | Liraglutide Type 1 diabetes | HbA1c ≤8.5% | Ph 3 | Completed | 1 | Apr 2014 | 13 | results |
| NCT01739049Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese | Liraglutide Feeding And Eating Disorders, Obesity / overweight | BMI 30-45 | Ph 4 | Completed | 1 | Oct 2013 | 1 | |
| GLP-1ADDSGLP-1 and Microvascular Function in Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c 7-8.5% | Not applicable | Completed | 1 | Dec 2015 | 1 | |
| NCT01744236SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 4 | Completed | 1 | Aug 2015 | 6 | |
| NCT01755416Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting | Liraglutide Type 1 diabetes | HbA1c ≤8.5% | Ph 2 | Completed | 1 | Jan 2015 | — | results |
| BOLTBlood Pressure Outcomes With Liraglutide Therapy | Liraglutide Hypertension, Type 2 diabetes | HbA1c 6.5-10% | Ph 4 | Completed | 1 | Jan 2014 | 1 | |
| MAGNA VICTORIAEffect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Mar 2016 | 51 | |
| LAED001Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users | Liraglutide Dyslipidemia, Type 2 diabetes | HbA1c 7-9.5% | Ph 4 | Completed | 1 | Mar 2014 | — | |
| LIDO52 Week Trial of Liraglutide in Type 1 Diabetes | Liraglutide Obesity / overweight, Type 1 diabetes | — | Ph 4 | Completed | 1 | Apr 2015 | 1 | results |
| NCT01789086A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years | Liraglutide Obesity / overweight | Age 12-17 | Ph 1 | Completed | 1 | May 2014 | 1 | |
| NCT01795248The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes | Liraglutide Gestational diabetes, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≤45 | Ph 4 | Completed | 1 | Sep 2019 | 19 | |
| NCT01832532A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks | Liraglutide Obesity / overweight, Sleep apnea | BMI ≥27 | Ph 1/2 | Completed | 1 | Dec 2015 | — | results |
| ELADEvaluating Liraglutide in Alzheimer's Disease | Liraglutide Alzheimer's / cognition | — | Ph 2 | Unknown | 1 | Dec 2019 | 3 | |
| GREATDoes a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? | Liraglutide Obesity / overweight, Prediabetes / glucose intolerance, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥27 | Ph 2 | Unknown | 1 | Mar 2016 | 3 | |
| NCT01847313The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease | GLP-1 / incretin class catch-all, Liraglutide Chronic kidney disease, Type 2 diabetes | — | Ph 3 | Completed | 1 | Nov 2015 | 25 | results |
| NCT01856790Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes | Liraglutide Type 1 diabetes | HbA1c ≤9% | Early Ph 1 | Completed | 1 | Nov 2015 | — | results |
| NCT01899430Polycystic Ovary Syndrome and Liraglutide | Liraglutide Obesity / overweight, PCOS | Female | Ph 4 | Completed | 1 | Oct 2012 | — | |
| NCT01911468Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, PCOS | Female | Ph 4 | Completed | 1 | Oct 2012 | 1 | |
| EGOFIPEffect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes. | Liraglutide Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Apr 2014 | 1 | |
| NCT01937598Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D | Liraglutide Type 2 diabetes | BMI 22-40 | Ph 3 | Completed | 1 | Apr 2014 | — | results |
| NCT01954147Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus | Liraglutide Type 2 diabetes | BMI ≤40 | Ph 1/2 | Unknown | 1 | Oct 2014 | 1 | |
| SIMPLEThe Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study | Liraglutide Type 2 diabetes | HbA1c ≥10% | Ph 4 | Completed | 1 | Dec 2017 | 1 | results |
| PRODIGIESPrevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines | Liraglutide Bariatric Surgery, Chronic kidney disease, Type 2 diabetes | BMI ≤35 | Not applicable | Unknown | 1 | Dec 2015 | — | |
| NCT02001363Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury | Liraglutide Cardiovascular disease | — | Not applicable | Unknown | 1 | Mar 2016 | 6 | |
| NCT02014740Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 4 | Completed | 1 | Mar 2017 | 1 | results |
| NCT02041234Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment | Liraglutide Bariatric Surgery, Obesity / overweight, Type 2 diabetes | BMI 27-32 | Ph 4 | Completed | 1 | Dec 2020 | 9 | |
| LYDIAEffects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 1 | Sep 2017 | 1 | |
| NCT02057172Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes | Efpeglenatide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 1 | Oct 2014 | 1 | |
| NCT02059564A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus | Efpeglenatide, Exenatide, Liraglutide Type 2 diabetes | BMI 18-45 | Ph 1 | Unknown | 1 | Oct 2014 | 1 | |
| NCT02077946A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Sep 2014 | 1 | |
| NCT02082496GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations | Liraglutide Hypothalamic / syndromic obesity, Obesity / overweight | BMI ≥28 | Ph 2 | Completed | 1 | Apr 2016 | — | |
| NCT02089256Effect of Repeated Administration of Liraglutide on Insulinogenic Indices | Liraglutide Healthy volunteers | — | Ph 4 | Completed | 1 | Mar 2015 | 3 | |
| T1DMLIRALiraglutide as add-on to Insulin in Type 1 Diabetes | Liraglutide Type 1 diabetes | BMI 18-28 | Ph 3 | Completed | 1 | Oct 2014 | 1 | |
| TODINELITreatment of Diabetic Neuropathy With Liraglutide | Liraglutide Diabetic neuropathy, Type 1 diabetes | BMI ≥22 | Not applicable | Completed | 1 | Feb 2017 | 4 | |
| NCT02150707The Differential Effects of Diabetes Therapy on Inflammation | Exenatide, Liraglutide Chronic kidney disease, Type 2 diabetes | — | — | Completed | 1 | Dec 2015 | 4 | |
| NCT02187250PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, PCOS | Female | Ph 4 | Completed | 1 | Jun 2014 | 1 | |
| NCT02207348Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors | Liraglutide Obesity / overweight | BMI ≥27 | Ph 1 | Completed | 1 | Sep 2014 | — | |
| NCT02235961Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects | Liraglutide Obesity / overweight | BMI 27-35 | Ph 1 | Completed | 1 | Jul 2016 | — | |
| NCT02244164Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. | Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | BMI 20-45 | Not applicable | Terminated | 1 | Feb 2023 | 4 | |
| NCT02255266Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Nov 2015 | 1 | |
| LiRA2The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure | Liraglutide Chronic kidney disease, Prediabetes / glucose intolerance | — | Ph 2 | Withdrawn | 1 | Aug 2015 | — | |
| NCT02299388To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study | Liraglutide Hypertension, Type 2 diabetes | HbA1c 7-10.5% | Ph 4 | Completed | 1 | Nov 2016 | — | results |
| LIONESSLiraglutide to Improve corONary Haemodynamics During Exercise streSS | GLP-1 / incretin class catch-all, Liraglutide Cardiovascular disease | — | Ph 2 | Completed | 1 | Mar 2015 | 2 | |
| NCT02324842Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c 7-10% | Not applicable | Completed | 1 | Mar 2018 | 2 | results |
| NCT02344186Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes | Liraglutide Obesity / overweight, Type 2 diabetes | BMI 27-35 | Ph 4 | Unknown | 1 | Dec 2022 | — | |
| NCT02408705Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects | Liraglutide Type 1 diabetes | BMI 20-25 | Ph 2 | Completed | 1 | May 2016 | 1 | |
| NCT02417103Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid | Liraglutide Bariatric Surgery Candidate, Obesity / overweight, Type 2 diabetes | BMI 35-55 | Ph 3 | Terminated | 1 | Sep 2016 | — | |
| NCT02456428Incretin-based Drugs and the Risk of Heart Failure | Exenatide, Liraglutide Type 2 diabetes | — | — | Completed | 1 | May 2015 | 1 | |
| PLAQUEPsoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study | Liraglutide Psoriasis / psoriatic arthritis | — | Ph 2 | Withdrawn | 1 | Oct 2016 | — | |
| LIRABONEThe Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function | Liraglutide Type 2 diabetes | — | Ph 4 | Completed | 1 | Oct 2017 | 7 | |
| NCT02475499Incretin-based Drugs and Pancreatic Cancer | Exenatide, Liraglutide Type 2 diabetes | — | — | Completed | 1 | Apr 2015 | 1 | |
| NCT02476760Incretin-based Drugs and Acute Pancreatitis | Exenatide, Liraglutide Type 2 diabetes | — | — | Completed | 1 | Apr 2015 | 1 | |
| NCT02483299Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome | Liraglutide Obesity / overweight, PCOS | Female | Ph 4 | Completed | 1 | Apr 2015 | — | |
| NCT02490176Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters | Liraglutide Heart failure | EF ≤50% | Not applicable | Unknown | 1 | Jul 2016 | 7 | |
| EGLIPAThe Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) | Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 4 | Unknown | 1 | Jul 2015 | 3 | |
| NCT02507128Effects of Glucagon Like Peptide-1 on No-reflow | Liraglutide Cardiovascular disease | — | Not applicable | Unknown | 1 | Jul 2016 | 5 | |
| NCT02516657Liraglutide in Adolescents With Type 1 Diabetes | Liraglutide Type 1 diabetes | HbA1c ≤10% | Ph 3 | Completed | 1 | Aug 2022 | — | results |
| NCT02518945Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes | Liraglutide Type 1 diabetes | HbA1c ≤11% | Ph 3 | Completed | 1 | Dec 2015 | 1 | results |
| LIRALBUAntiproteinuric Effects of Liraglutide Treatment | Liraglutide Chronic kidney disease, Type 2 diabetes | eGFR ≥30 | Ph 4 | Completed | 1 | May 2016 | 3 | |
| NCT02577848GLP-1 on Non-ST-Segment Elevation Myocardial Infarction | Liraglutide Cardiovascular disease | — | Not applicable | Unknown | 1 | Oct 2016 | 5 | |
| GAPGlucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis | Liraglutide Cardiovascular disease, Obesity / overweight | BMI ≥25 | Ph 4 | Completed | 1 | Apr 2017 | 23 | |
| NCT02616003Preoperative Condition in Giant Obese Patients | Liraglutide Bariatric Surgery Candidate, Obesity / overweight | — | Ph 4 | Completed | 1 | Jan 2018 | 7 | |
| NCT02647944Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | Liraglutide Obesity / overweight | Healthy volunteers | Ph 2 | Completed | 1 | Dec 2016 | 3 | results |
| NCT02650206Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood | Liraglutide Obesity / overweight, Type 2 diabetes | BMI 25-42 | Ph 1 | Completed | 1 | Sep 2019 | — | |
| NCT02650596Effects of GLP-1 on Chronic Heart Failure | Liraglutide Heart failure, Type 2 diabetes | — | Not applicable | Unknown | 1 | Feb 2018 | 3 | |
| CGH-LiNASHComparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults | GLP-1 / incretin class catch-all, Liraglutide Bariatric Surgery, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27.5 | Ph 3 | Unknown | 1 | Dec 2017 | 1 | |
| NCT02655770Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients | Liraglutide Heart failure, Type 2 diabetes | EF ≥50% | Ph 4 | Completed | 1 | Dec 2019 | 10 | |
| MAGNA VICTORIAEffect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 4 | Completed | 1 | Mar 2018 | 5 | |
| GLP1 et GoûtEffect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes | Liraglutide Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 4 | Terminated | 1 | Aug 2016 | 1 | |
| ANGIOSAFE 1Effect of GLP-1 on Angiogenesis | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Aug 2017 | 1 | |
| NCT02717858A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects. | Liraglutide Obesity / overweight | BMI ≥27 | Ph 1 | Completed | 1 | Feb 2017 | 1 | |
| LIRA-NAFLD/LIPEffect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism | Liraglutide Dyslipidemia, Type 2 diabetes | HbA1c ≥7% | Ph 4 | Terminated | 1 | Oct 2019 | 3 | |
| NCT02743598Liraglutide for HIV-associated Neurocognitive Disorder | Liraglutide HIV, Obesity / overweight, Type 2 diabetes | BMI 27-45 | Ph 4 | Terminated | 1 | Jun 2018 | — | |
| NCT02765399The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis | Liraglutide Obesity / overweight, Type 2 diabetes | BMI 27-40 | Ph 4 | Completed | 1 | Feb 2019 | 6 | results |
| 1974Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes | Liraglutide Type 1 diabetes | HbA1c ≤8.5% | Not applicable | Completed | 1 | Dec 2016 | — | results |
| LIRAVISShort Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c ≥7% | Ph 4 | Completed | 1 | Sep 2016 | — | |
| NCT02879409HbA1c Variability in Type II Diabetes | Liraglutide Type 2 diabetes | BMI 26-36 | Not applicable | Active, not recruiting | 1 | Oct 2023 | 29 | |
| LOSEITLiraglutide 3 mg for Knee Osteoarthritis | Liraglutide Obesity / overweight, Osteoarthritis | BMI ≥27 | Ph 4 | Completed | 1 | Feb 2019 | 4 | |
| NCT02909933Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity | Liraglutide Obesity / overweight, PCOS | Female | Ph 4 | Completed | 1 | Oct 2015 | 1 | |
| NCT02910570Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis | Liraglutide Obesity / overweight, Osteoarthritis | BMI ≥27 | Ph 4 | Completed | 1 | Feb 2019 | — | |
| MODELLifestyle Modification and Liraglutide | Liraglutide Obesity / overweight | BMI 30-55 | Ph 4 | Completed | 1 | Nov 2018 | 3 | results |
| IM-LOSEIT-IMulti-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss | Liraglutide Obesity / overweight, Osteoarthritis | — | — | Completed | 1 | Feb 2019 | — | |
| BIO-LOSEIT-IIBiomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance | Liraglutide Obesity / overweight, Osteoarthritis | — | Ph 4 | Completed | 1 | Feb 2019 | — | |
| IM-LOSEIT-IIMulti-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance | Liraglutide Obesity / overweight, Osteoarthritis | — | Ph 4 | Completed | 1 | Feb 2019 | — | |
| NCT02930265Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy | Liraglutide Cardiovascular disease, Heart failure | EF ≤40% | Not applicable | Unknown | 1 | Feb 2018 | 15 | |
| BIO-LOSEIT-IBiomarkers in Obese Patients With Knee Osteoarthritis; Weight Loss | Liraglutide Obesity / overweight, Osteoarthritis | — | Not applicable | Unknown | 1 | Jan 2019 | — | |
| US-LOSEIT-IUltrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss | Liraglutide Obesity / overweight, Osteoarthritis | BMI ≥27 | — | Completed | 1 | Feb 2019 | — | |
| US-LOSEIT-IIUltrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance | Liraglutide Obesity / overweight, Osteoarthritis | BMI ≥27 | Ph 4 | Completed | 1 | Feb 2019 | — | |
| NCT02953665Safety and Efficacy of Liraglutide in Parkinson's Disease | Liraglutide Parkinson's disease | — | Ph 2 | Completed | 1 | Aug 2022 | 1 | results |
| CIMT-LOSEIT-IUltrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss | Liraglutide Obesity / overweight, Osteoarthritis | BMI ≥27 | — | Completed | 1 | Feb 2019 | — | |
| NCT02960659Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes | Liraglutide Type 2 diabetes | HbA1c ≤9% | Ph 1/2 | Completed | 1 | May 2022 | 1 | results |
| NCT03010683Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus | Liraglutide Cardiovascular disease, Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes | BMI ≥30 | Not applicable | Completed | 1 | Jun 2017 | 2 | results |
| NCT03011008Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus | Liraglutide Type 1 diabetes | — | Ph 4 | Unknown | 1 | Dec 2020 | 3 | |
| NCT03011021Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes | Liraglutide Type 1 diabetes | — | Ph 1/2 | Unknown | 1 | Jun 2025 | 6 | |
| NCT03034941Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients | Liraglutide Obesity / overweight, PCOS, Reproductive / infertility | Female | Ph 4 | Completed | 1 | Dec 2016 | 3 | |
| NCT03038620Impact of Liraglutide 3.0 on Body Fat Distribution | Liraglutide Metabolic syndrome, Obesity / overweight | BMI ≥30 | Ph 4 | Completed | 1 | Oct 2020 | 26 | results |
| NCT03041792Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects | Liraglutide Obesity / overweight | BMI 30-40 | Ph 1 | Completed | 1 | Jan 2018 | — | results |
| NCT03048578Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery | Liraglutide Bariatric Surgery, Obesity / overweight | — | Ph 4 | Completed | 1 | Mar 2021 | — | results |
| NCT03068065Antidiabetic Effects on Intrahepatic Fat | Liraglutide MASH / NAFLD / liver fibrosis, Type 2 diabetes | BMI 20-35 | Ph 4 | Completed | 1 | Nov 2014 | — | |
| NCT03101930Cardiovascular Effects of GLP-1 Receptor Activation | Liraglutide Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥30 | Ph 4 | Completed | 1 | Jun 2021 | — | results |
| NCT03115424Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy | GLP-1 / incretin class catch-all, Liraglutide Bariatric Surgery, Obesity / overweight | — | Ph 3 | Completed | 1 | Oct 2023 | — | results |
| NCT03151005The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, PCOS | BMI ≥24 | Ph 4 | Completed | 1 | Apr 2021 | 12 | results |
| NCT03158805Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) | Liraglutide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥30 | Ph 2 | Completed | 1 | Oct 2022 | 1 | results |
| NCT03208881Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness | Liraglutide Obesity / overweight, Osteoarthritis | BMI ≥27 | — | Unknown | 1 | Jan 2019 | — | |
| MRBMedically Reproducing Bariatric Surgery | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 2 | Completed | 1 | Oct 2018 | 6 | |
| ALTMeasurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Jun 2017 | 1 | |
| NCT03260881Liraglutide Effects on Epicardial Fat Inflammatory Genes | Liraglutide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 4 | Completed | 1 | Sep 2024 | — | results |
| BELIEVEBinge Eating Liraglutide Intervention | GLP-1 / incretin class catch-all, Liraglutide Feeding And Eating Disorders, Obesity / overweight | BMI 27-29.9 | Ph 3 | Terminated | 1 | Sep 2019 | — | results |
| BARIOPTIMISEEvaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response | Liraglutide Bariatric Surgery, Obesity / overweight | — | Ph 4 | Completed | 1 | Nov 2019 | 19 | |
| LIRAOBReward Mechanisms in Obesity | Liraglutide Healthy volunteers, Obesity / overweight | BMI 30-40 | Ph 4 | Completed | 1 | Mar 2020 | — | |
| NCT03374956Individualized Obesity Pharmacotherapy | Liraglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 1 | May 2022 | 1 | results |
| LIRAFLAMEEffect of Liraglutide on Vascular Inflammation in Type-2 Diabetes | Liraglutide Type 2 diabetes | eGFR ≥30 | Ph 4 | Completed | 1 | Aug 2019 | 4 | |
| NCT03479762In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database | Liraglutide Obesity / overweight | — | — | Completed | 1 | Sep 2022 | — | |
| SAXAPCOSLiraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS | Liraglutide Obesity / overweight, PCOS | BMI ≥30 | Ph 3 | Completed | 1 | Feb 2021 | 1 | results |
| NCT03492580A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Cardiovascular disease, Type 2 diabetes | Established CVD | — | Completed | 1 | Apr 2018 | — | |
| LICAS-MREffects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging | Dulaglutide, Liraglutide, Semaglutide Type 2 diabetes | BMI ≥30 | Not applicable | Completed | 1 | Jun 2023 | 1 | |
| NCT03500484Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity. | Liraglutide Healthy volunteers, Obesity / overweight | BMI 18.5-24.9 | Early Ph 1 | Terminated | 1 | Jun 2020 | — | results |
| LIRAPThe Effect of Liraglutide on Pancreatic Hormones and Its Size | Liraglutide Obesity / overweight | BMI ≥26 | Not applicable | Completed | 1 | Apr 2019 | — | |
| NCT03523273Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity | Liraglutide Obesity / overweight | Healthy volunteers | Ph 2 | Completed | 1 | Aug 2021 | — | results |
| LETHEWeight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg | Liraglutide Bariatric Surgery Candidate, Obesity / overweight | BMI ≥35 | Not applicable | Completed | 1 | Jan 2017 | — | |
| NCT03619330Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism. | Liraglutide Obesity / overweight, Reproductive / infertility | BMI ≥30 | Ph 4 | Completed | 1 | Aug 2015 | — | |
| NCT03642600The Gut Microbiome in Women With Polycystic Ovary Syndrome | Liraglutide Obesity / overweight, PCOS | BMI ≥27 | Ph 4 | Completed | 1 | Feb 2020 | — | |
| NCT03671733Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients | Exenatide, Liraglutide Obesity / overweight | BMI ≥28 | Ph 3 | Unknown | 1 | Sep 2022 | — | |
| NCT03707171Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus | Liraglutide Type 2 diabetes | — | Ph 3 | Completed | 1 | Feb 2019 | 1 | |
| DALDaily Liraglutide for Nicotine Dependence | Liraglutide Alcohol / substance use, Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 1 | May 2022 | — | results |
| NCT03799198Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity | Liraglutide Obesity / overweight | — | Ph 4 | Completed | 1 | May 2020 | 2 | results |
| NCT03804411Prognostic Predictors of Response to Hypoglycemic Therapy | Exenatide, Liraglutide Type 2 diabetes | HbA1c ≤1% | Ph 4 | Unknown | 1 | Mar 2020 | — | |
| LEAFLiraglutide Effect in Atrial Fibrillation | Liraglutide Atrial fibrillation, Obesity / overweight | BMI ≥27 | Ph 4 | Active, not recruiting | 1 | Dec 2026 | 1 | |
| ZQL007Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | Liraglutide Type 2 diabetes | HbA1c ≤8.5% | Ph 4 | Unknown | 1 | Jun 2025 | 44 | |
| NCT038852973mg Liraglutide for Overweight or Obesity | Liraglutide Obesity / overweight | BMI ≥30 | — | Completed | 1 | Dec 2020 | 9 | |
| NCT03936049Replication of the LEADER Diabetes Trial in Healthcare Claims | Liraglutide Cardiovascular disease, Type 2 diabetes | — | — | Completed | 1 | Feb 2021 | 1 | |
| LAMPLiraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus | Liraglutide Stroke, Type 2 diabetes | — | Not applicable | Unknown | 1 | Dec 2023 | 2 | |
| NCT03986008Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients | Beinaglutide, Liraglutide Obesity / overweight | BMI ≥28 | Ph 3 | Unknown | 1 | Dec 2021 | — | |
| NCT03993132A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes | Liraglutide Type 2 diabetes | — | — | Completed | 1 | Jun 2022 | 1 | results |
| NCT04020445Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c ≤7.5% | — | Completed | 1 | Jan 2022 | 1 | |
| NCT04034524Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | — | — | Unknown | 1 | Dec 2020 | — | |
| NCT04046822Effect of Liraglutide on Microbiome in Obesity | Liraglutide Obesity / overweight | BMI ≥30 | Ph 4 | Unknown | 1 | Jan 2020 | 5 | |
| LirabolicEffect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease | Liraglutide Cardiovascular disease, Type 2 diabetes | HbA1c ≥7% | Ph 3 | Withdrawn | 1 | Aug 2022 | — | |
| S-LITECombined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet | GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight | BMI 32-43 | Ph 4 | Unknown | 1 | Nov 2019 | 61 | |
| NCT04146155Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease | Liraglutide Cardiovascular disease, Type 2 diabetes | HbA1c ≤14% | Ph 4 | Unknown | 1 | Dec 2021 | 1 | |
| NCT04184947Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | — | Completed | 1 | Dec 2018 | 1 | |
| NCT04186494Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea | Liraglutide Obesity / overweight, Sleep apnea | BMI 30-40 | Not applicable | Completed | 1 | Dec 2021 | 1 | |
| BEYONDDurability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) | GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | HbA1c ≥7.5% | Ph 4 | Completed | 1 | Sep 2020 | 3 | |
| NCT04199728Use of a GLP-1R Agonist to Treat Opioid Use Disorder | Liraglutide Alcohol / substance use | — | Ph 1/2 | Completed | 1 | Sep 2023 | 1 | results |
| NCT04417582Life Style Modification Medical and Surgical Management in Patients With Obesity | Liraglutide Bariatric Surgery, Obesity / overweight | BMI 18-65 | — | Unknown | 1 | Dec 2023 | — | |
| NCT04487743Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities | Liraglutide Obesity / overweight | BMI ≥30 | Ph 3 | Unknown | 1 | Jun 2022 | — | |
| NCT04525300Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities | Liraglutide Obesity / overweight | BMI ≥30 | Ph 3 | Unknown | 1 | Jun 2022 | — | |
| EMPOWER-T2DEMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 4 | Terminated | 1 | Aug 2022 | — | results |
| NATRIURETICIncretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial | Liraglutide Type 2 diabetes | BMI 18.5-40 | Ph 2 | Unknown | 1 | Oct 2023 | — | |
| NCT04575194Study of the Cardiometabolic Effects of Obesity Pharmacotherapy | Liraglutide Obesity / overweight | BMI ≥30 | Ph 4 | Unknown | 1 | Sep 2022 | 1 | |
| ZQL008Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome | Liraglutide Metabolic syndrome, Obesity / overweight | BMI 25-35 | Ph 4 | Recruiting | 1 | Apr 2027 | 38 | |
| NCT04605861The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients | Liraglutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 1 | Dec 2022 | — | |
| Lean-DMTargeting Beta-cell Failure in Lean Patients With Type 2 Diabetes | Liraglutide Obesity / overweight, Type 2 diabetes | BMI ≤25 | Ph 4 | Completed | 1 | Oct 2022 | 1 | |
| NCT04763564Efficacy of Liraglutide Therapy in Patients With IPAA | Liraglutide Gastrointestinal (gastroparesis / short bowel / pancreatitis) | — | Ph 2 | Terminated | 1 | Oct 2023 | 1 | results |
| NCT04781998Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry? | Liraglutide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥27 | Ph 4 | Completed | 1 | Jul 2022 | — | |
| NCT04829903Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin | Dulaglutide, Liraglutide Obesity / overweight, Type 2 diabetes | — | Not applicable | Completed | 1 | Mar 2021 | — | |
| NCT04839237The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients | Liraglutide Obesity / overweight | BMI ≥28 | Ph 2 | Withdrawn | 1 | Dec 2020 | — | |
| STARDUSTLiraglutide and Peripheral Artery Disease | Liraglutide Cardiovascular disease, Type 2 diabetes | HbA1c 6.5-8% | Ph 4 | Completed | 1 | Dec 2022 | 2 | results |
| NCT04883346Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy | Liraglutide Bariatric Surgery, Obesity / overweight | — | Ph 2 | Completed | 1 | Mar 2024 | 3 | results |
| NCT04903509A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide | Liraglutide Healthy volunteers, Obesity / overweight | BMI 25-34.9 | Ph 1 | Completed | 1 | Aug 2022 | — | |
| NCT05029076Human Bioequivalence Test of Liraglutide Injection | Liraglutide Healthy volunteers | BMI 18-28 | Ph 1 | Completed | 1 | Jun 2019 | 1 | |
